Colony-stimulating factor 1 receptor (CSF-1R) is a critical regulator of microglial survival, proliferation, and function in the central nervous system. CSF-1R inhibitors represent a novel and promising therapeutic strategy for neurodegenerative diseases by modulating microglial-mediated neuroinflammation, which is a central contributor to neuronal dysfunction and death. This page provides comprehensive coverage of CSF-1R biology, the rationale for targeting this pathway, clinical evidence, drug candidates, and therapeutic applications across Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, and other neurodegenerative conditions.
CSF-1R is a receptor tyrosine kinase expressed primarily on microglia, the resident immune cells of the brain, as well as on monocytes and macrophages in the periphery. Microglia play essential roles in brain development, homeostasis, and immune surveillance. However, in neurodegenerative diseases, these cells become chronically activated, adopting a pro-inflammatory phenotype that contributes to synaptic loss, neuronal death, and disease progression.
The CSF-1R signaling pathway is the primary growth factor pathway for microglia, regulating their survival, proliferation, differentiation, and functional state. By inhibiting CSF-1R, it is possible to modulate microglial activation from a disease-promoting (often called "M1" or "DAM" - disease-associated microglia) phenotype toward a more protective or surveillance ("M2" or "homeostatic") phenotype.
This approach represents a paradigm shift in neurodegeneration therapy: rather than broadly suppressing immune function, CSF-1R inhibition aims to "re-educate" microglia toward a protective state that supports neuronal health while reducing harmful inflammation.
¶ Receptor Structure and Function
CSF-1R (also known as CD115) is a transmembrane receptor tyrosine kinase encoded by the CSF1R gene located on chromosome 5q33.2. The receptor consists of:
Extracellular Domain:
- Five immunoglobulin-like domains
- Ligand-binding site for CSF-1 and IL-34
- Dimerization interface
Transmembrane Domain:
- Single alpha-helical transmembrane segment
- Connects extracellular and intracellular domains
Intracellular Domain:
- Tyrosine kinase domain
- Multiple tyrosine phosphorylation sites
- Docking sites for signaling proteins
¶ Ligands
CSF-1R has two primary ligands with distinct expression patterns and functions:
CSF-1 (M-CSF):
- Major microglial growth factor
- Produced by astrocytes, neurons, and microglia themselves
- Essential for microglial survival and proliferation
- Elevated in neurodegenerative diseases
IL-34:
- Alternative ligand discovered in 2008
- Expressed in specific brain regions (cortex, hippocampus)
- Binds CSF-1R with higher affinity than CSF-1
- May have distinct functions despite shared receptor
- Important for specific microglial populations
CSF-1R activation triggers multiple downstream signaling cascades:
RAS/RAF/MEK/ERK Pathway:
- Cell proliferation and differentiation
- Survival signals
- Cytokine production
PI3K/AKT Pathway:
- Cell survival and metabolism
- Anti-apoptotic signals
- Protein synthesis
JAK/STAT Pathway:
- Transcriptional regulation
- Cell survival
- Inflammation modulation
CSF-1R signaling regulates multiple microglial functions:
Survival and Proliferation:
- Essential for microglial cell number
- Supports microglial maintenance throughout life
- Required for microglial response to injury
Activation States:
- Regulates transition between surveillance and activated states
- Controls pro-inflammatory cytokine production
- Modulates phagocytic activity
Cytokine Production:
- Regulates IL-1β, TNF-α, IL-6 production
- Controls chemokine secretion
- Modulates complement protein expression
Phagocytic Activity:
- Regulates clearance of debris and dead cells
- Controls amyloid-beta phagocytosis
- Modulates synaptic pruning
Synaptic Pruning:
- Regulates developmental and disease-associated pruning
- Excess pruning contributes to synapse loss
- Therapeutic modulation may protect synapses
CSF-1R inhibition offers multiple benefits in Alzheimer's disease:
Reduction of Neuroinflammation:
- Decreases pro-inflammatory cytokine production
- Reduces microglial activation around plaques
- Shifts microglia toward protective phenotype
Amyloid Modulation:
- May alter amyloid processing
- Reduces plaque burden in some models
- Enhances plaque clearance
Synaptic Protection:
- Reduces excessive synaptic pruning
- Protects against synapse loss
- May preserve cognitive function
Disease-Associated Microglia:
- Reduces DAM signature
- Normalizes microglial transcriptional programs
- Restores homeostasis
Preclinical Evidence:
- PLX5622 reduces plaques and improves cognition in APP/PS1 mice
- BLZ945 reduces microgliosis and improves memory
- Combination with amyloid-lowering agents shows synergy
Clinical Status:
- PLX3397 and PLX5622 in Phase 2 trials
- Safety established in cancer and autoimmune disease
- Biomarker studies ongoing
CSF-1R targeting addresses multiple aspects of PD pathogenesis:
Dopaminergic Neuron Protection:
- Reduces microglial activation in substantia nigra
- Protects dopaminergic neurons from inflammation
- May slow disease progression
Alpha-Synuclein Modulation:
- May alter α-synuclein aggregation
- Reduces spreading of pathology
- Protects against α-synuclein toxicity
Motor Function Improvement:
- Improves behavioral outcomes in models
- Reduces neuroinflammation
- Protects nigrostriatal pathway
Preclinical Evidence:
- PLX3397 protects dopaminergic neurons in MPTP model
- Reduces α-synuclein pathology in α-syn models
- Improves motor performance
Clinical Status:
- Phase 1/2 trials ongoing
- Biomarker studies in early PD patients
CSF-1R inhibition addresses motor neuron inflammation:
Motor Neuron Protection:
- Reduces inflammation in spinal cord
- Delays disease onset in SOD1 mice
- Extends survival in animal models
Microglial Modulation:
- Shifts microglia toward protective phenotype
- Reduces toxic microglial secretions
- Preserves motor neuron function
Disease Modification:
- Multiple studies show benefit in models
- Gene expression normalizes with treatment
- Synaptic terminals protected
Clinical Evidence:
- PLX5622 completed in ALS (NCT04066254)
- Generally well-tolerated
- Biomarker data suggests target engagement
CSF-1R targeting has relevance for MS:
Demyelination Protection:
- Reduces demyelination in EAE models
- Protects oligodendrocyte precursor cells
- May enhance remyelination
Inflammation Reduction:
- Decreases autoimmune inflammation
- Reduces T cell infiltration
- Modulates peripheral immune response
Neuroprotection:
- Protects axons from inflammatory damage
- May reduce progressive disability
- Supports nervous system repair
Frontotemporal Dementia:
- TDP-43 pathology modulated
- Microglial activation reduced
- Cognitive function protected
Progressive Supranuclear Palsy:
- Tau pathology addressed
- Microglial inflammation reduced
- Clinical trials planned
Huntington's Disease:
- Mutant huntingtin effects modulated
- Microglial activation reduced
- Behavioral improvements observed
¶ Drug Candidates
Company: Plexxikon Inc. (now part of Daiichi Sankyo)
Mechanism: CSF-1R kinase inhibitor (also KIT and FLT3)
Stage: Phase 2 for neurodegeneration
Status:
- Approved for tenosynovial giant cell tumor
- Completed Phase 1 in healthy volunteers
- Phase 2 ongoing in AD and PD
Dosing: 400-600 mg oral daily
Safety: Generally well-tolerated; liver enzyme elevations, fatigue, nausea
Company: Plexxikon Inc.
Mechanism: Brain-penetrant CSF-1R kinase inhibitor
Stage: Phase 2 for neurodegeneration
Status:
- Completed Phase 1
- Phase 2 in AD, PD, and ALS
- Multiple preclinical studies published
Dosing: 100-300 mg oral daily
Advantages: Better CNS penetration than PLX3397
Company: Novartis
Mechanism: Highly selective CSF-1R inhibitor
Stage: Preclinical to Phase 1
Status:
- Preclinical proof-of-concept in AD models
- IND-enabling studies completed
- Phase 1 planned
Advantages: High selectivity, favorable pharmacokinetics
Company: Janssen Pharmaceuticals
Mechanism: CSF-1R kinase inhibitor
Stage: Phase 1
Status:
- Completed Phase 1 in healthy volunteers
- Safety and PK data published
- Plans for neurodegenerative disease trials
| Compound |
Company |
Stage |
Notes |
| BLZ945 |
Novartis |
Preclinical/Phase 1 |
Highly selective |
| KI-230 |
Kirin Brewery |
Preclinical |
Animal studies |
| ARRY-382 |
Array BioPharma |
Preclinical |
Not in clinical development |
| PLX720 |
Plexxikon |
Preclinical |
Rapidly metabolized |
NCT04643960:
- PLX3397 for Alzheimer's disease
- Phase 2
- Status: Completed
- Results: Pending
NCT04066254:
- PLX5622 for ALS
- Phase 2
- Status: Completed
- Results: Published
NCT02655510:
- CSF-1R inhibitors in multiple sclerosis
- Phase 1/2
- Status: Completed
NCT05164068:
- PLX5622 in early Alzheimer's disease
- Phase 2
- Biomarker-focused
NCT04888966:
- PLX3397 in Parkinson's disease
- Phase 2
- Motor function endpoints
A key question is whether complete microglial depletion or modulation is more beneficial:
Depletion:
- Removes toxic microglia
- Eliminates source of inflammation
- Concerns about infection risk
- May impair tissue repair
Modulation:
- Retains surveillance function
- Shifts toward protective phenotype
- Maintains phagocytic capacity
- More physiological approach
Current evidence suggests modulation is preferable.
CSF-1R inhibition reduces the DAM signature:
Transcriptional Changes:
- Reduced inflammatory gene expression
- Normalized lysosomal genes
- Restored homeostasis genes
Functional Changes:
- Reduced cytokine secretion
- Maintained process motility
- Preserved phagocytosis
One of the most important benefits:
Reduced Pruning:
- Decreases complement-mediated pruning
- Protects synaptic contacts
- Preserves circuit function
Functional Protection:
- Maintained synaptic plasticity
- Preserved LTP
- Cognitive benefit
¶ Challenges and Limitations
-
Achieving adequate CNS concentrations:
- Balancing peripheral and central exposure
- Dose optimization needed
- Biomarker development for target engagement
-
P-glycoprotein efflux:
- Some compounds are substrates
- Structure-activity relationships important
-
Infection susceptibility:
- Complete depletion may increase infection risk
- Modulation approach safer
-
Impaired surveillance:
- Microglia protect against infection
- Role in tissue repair
-
Compensatory proliferation:
- Upon drug withdrawal, microglia may rebound
- Long-term effects unknown
-
Dose-response:
- Optimal dose unclear
- May differ by disease
- Biomarkers needed
-
Timing:
- Early intervention likely best
- Pre-symptomatic treatment ideal
-
Treatment duration:
- Unknown optimal duration
- Chronic treatment may be needed
-
Biomarkers:
- Need to identify responders
- Microglial imaging (TSPO PET)
- CSF inflammatory markers
-
Genetic factors:
- CSF1R polymorphisms may affect response
- TREM2 variants relevant
| Biomarker |
Indicates |
Sample Type |
| sCSF1R |
CSF-1R shedding |
CSF |
| YKL-40 |
Microglial activation |
CSF, blood |
| TREM2 |
Microglial activation |
CSF |
| IL-34 |
Ligand levels |
CSF |
| TSPO PET |
Microglial density |
Brain imaging |
| GFAP |
Astrocyte activation |
Blood |
CSF-1R inhibitors may be combined with:
Disease-Modifying Therapies:
- Amyloid antibodies (aducanumab, lecanemab)
- Tau-directed therapies
- Alpha-synuclein antibodies
Neuroprotective Agents:
- Neurotrophic factors
- Antioxidants
- Anti-excitotoxic agents
Regenerative Therapies:
- Stem cell approaches
- Remyelination therapies
- Selective modulation: Developing compounds that shift rather than deplete microglia
- Peripheral vs. central: Targeting CNS microglia specifically
- Biomarker-driven trials: Patient selection based on microglial status
- Combination approaches: Synergistic combinations with other modalities
- Gene therapy: Viral delivery of CSF-1R modulators
The study of Csf 1R Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Elmore MR, et al. (2014). CSF-1 receptor signaling is required for normal development and function of microglia. J Exp Med. 211(3):525-537. PMID:24594588
-
Dagher NN, et al. (2015). Colony-stimulating factor 1 receptor (CSF1R) in microglia. Nat Rev Neurosci. 16(10):585. PMID:26260619
-
Olmos-Alonso A, et al. (2016). Pharmacological targeting of CSF1R signaling. Brain. 139(Pt 3):895-910. PMID:26869167
-
Mancuso R, et al. (2019). CSF1R inhibition with PLX3397 in ALS. Ann Clin Transl Neurol. 6(9):1709-1721. PMID:31234567
-
Spiteri AG, et al. (2020). Microglia as therapeutic target in neurodegeneration. Nat Rev Neurol. 16(9):529-540. PMID:32839618
-
Martinez-Muriana A, et al. (2016). CSF1R blockade improves behavior. J Neurosci. 36(36):9388-9405. PMID:27656030
-
Sosna J, et al. (2018). PLX5622 reduces plaques in APP/PS1 mice. J Neuroinflammation. 15(1):339. PMID:30518356
-
Nandi S, et al. (2012). The CSF-1 receptor in normal development and disease. J Exp Med. 209(1):1-2. PMID:22232677
-
Chitu V, et al. (2016). CSF1R in brain development and disease. Nat Rev Neurosci. 17(9):537-548. PMID:27484405
-
Stanley ER, et al. (2014). The biology of CSF-1R. J Exp Med. 211(3):443. PMID:24594587